Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) — Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced that it has successfully completed a Type C meeting with the U.S. Food and Drug Administration (FDA). This results in meaningful regulatory alignment for clinical efficacy expectations, potency […]